epoetin alfa

(redirected from Epogen)
Also found in: Medical.
Related to Epogen: Neupogen, Procrit

e·po·e·tin al·fa

 (ĭ-pō′ĭ-tĭn ăl′fə)
A recombinant preparation of human erythropoietin used to treat some forms of anemia.

[e(rythro)po(i)etin + alteration of alpha.]

epoetin alfa

n epoetina alfa
Mentioned in ?
References in periodicals archive ?
EPOGEN along with Aranesp(R) have accumulated over 4 million combined patient years of experience.
Nevertheless, sales of Amgen's other high-profile anemia drugs - Epogen, Aranesp, Neulasta and Neupogen - jumped 50 percent, the company said.
Some $2 billion in annual sales are about evenly derived from Epogen and Neupogen.
Toru Sasahara, president of Kirin Pharmaceutical Division, said "I believe this will be a promising joint effort for Kirin and Amgen again as we have established on EPOGEN and NEUPOGEN.
Other anemia products, including Amgen's Epogen and Johnson & Johnson's Procrit are administered one to three times a week.
Considered Amgen's pre-eminent product, Aranesp is the company's next-generation Epogen.
EPOGEN (Epoetin alfa) is indicated for the treatment of anemia in patients with chronic renal failure on dialysis.
The Court of Appeals affirmed on Monday a district court's finding that two of Amgen's patents were infringed upon relating to anemia drug Epogen.
Of the larger licensing pacts, Amgen's Epogen is sold by Johnson & Johnson under the name Procrit.
Sales of the next-generation form of Epogen increased 29 percent to $672 million from $520 million for the third quarter of 2001.
on Wednesday, enabling a competitor to manufacture a drug similar to the biotechnology giant's blockbuster Epogen.